ja_mageia

NEUROFIBROMATOSIS CLINICAL RESEARCH AWARDS

The 2011 Call for Letters of Intent is now CLOSED. Look for further program announcements in 2012!

 

2011 Funded Clinical Trial Awards
 

Phase II Trial of Rapamycin - NF2 Tumors
Dr. Matthias Karajannis, New York University Langone Medical Center

New metrics for optic pathway glioma trials
Dr. Robert Avery, Children’s National Medical Center

Blood predictors of NF1 severity
Dr. Cynthia Hingtgen, Indiana University

Computerized ‘maze’ for NF1 learning disabilities trials
Dr. Nicole Ullrich, Children’s Hospital Boston


2009 Funded Clinical Trial Awards

Phase 0 Trial of Tykerb (Lapatinib) for NF2 Vestibular Schwannoma
Principal Investigators: Dr. Jaishri Blakeley (Johns Hopkins University) and Dr. Matthias Karajannis (New York University Langone Medical Center)
Collaborating Sites: Ohio State University, and the House Ear Institute. GlaxoSmithKline is providing the drug as well as technical support for the study.  

Phase I Trial of Nexavar (Sorafenib) for NF1 Plexiform Neurofibroma
Principal Investigators: Dr. Bruce Korf (University of Alabama at Birmingham), Dr. Aerang Kim and Dr. Brigitte Widemann at (NIH-NCI)  
Collaborating site: Children’s Hospital of Philadelphia